QQQ   292.10 (-1.40%)
AAPL   143.68 (-1.54%)
MSFT   243.68 (-1.81%)
META   148.00 (-2.46%)
GOOGL   97.45 (-1.93%)
AMZN   101.01 (-1.20%)
TSLA   173.24 (-2.62%)
NVDA   195.21 (-4.14%)
NIO   12.14 (-4.48%)
BABA   112.21 (-5.21%)
AMD   73.73 (-2.21%)
T   20.06 (+0.55%)
MU   62.07 (-2.82%)
F   13.06 (-1.58%)
CGC   2.90 (-1.02%)
GE   81.86 (-1.65%)
DIS   108.49 (-0.96%)
AMC   5.04 (-8.53%)
PFE   43.63 (-0.37%)
PYPL   80.85 (-1.20%)
NFLX   356.71 (-1.13%)
QQQ   292.10 (-1.40%)
AAPL   143.68 (-1.54%)
MSFT   243.68 (-1.81%)
META   148.00 (-2.46%)
GOOGL   97.45 (-1.93%)
AMZN   101.01 (-1.20%)
TSLA   173.24 (-2.62%)
NVDA   195.21 (-4.14%)
NIO   12.14 (-4.48%)
BABA   112.21 (-5.21%)
AMD   73.73 (-2.21%)
T   20.06 (+0.55%)
MU   62.07 (-2.82%)
F   13.06 (-1.58%)
CGC   2.90 (-1.02%)
GE   81.86 (-1.65%)
DIS   108.49 (-0.96%)
AMC   5.04 (-8.53%)
PFE   43.63 (-0.37%)
PYPL   80.85 (-1.20%)
NFLX   356.71 (-1.13%)
QQQ   292.10 (-1.40%)
AAPL   143.68 (-1.54%)
MSFT   243.68 (-1.81%)
META   148.00 (-2.46%)
GOOGL   97.45 (-1.93%)
AMZN   101.01 (-1.20%)
TSLA   173.24 (-2.62%)
NVDA   195.21 (-4.14%)
NIO   12.14 (-4.48%)
BABA   112.21 (-5.21%)
AMD   73.73 (-2.21%)
T   20.06 (+0.55%)
MU   62.07 (-2.82%)
F   13.06 (-1.58%)
CGC   2.90 (-1.02%)
GE   81.86 (-1.65%)
DIS   108.49 (-0.96%)
AMC   5.04 (-8.53%)
PFE   43.63 (-0.37%)
PYPL   80.85 (-1.20%)
NFLX   356.71 (-1.13%)
QQQ   292.10 (-1.40%)
AAPL   143.68 (-1.54%)
MSFT   243.68 (-1.81%)
META   148.00 (-2.46%)
GOOGL   97.45 (-1.93%)
AMZN   101.01 (-1.20%)
TSLA   173.24 (-2.62%)
NVDA   195.21 (-4.14%)
NIO   12.14 (-4.48%)
BABA   112.21 (-5.21%)
AMD   73.73 (-2.21%)
T   20.06 (+0.55%)
MU   62.07 (-2.82%)
F   13.06 (-1.58%)
CGC   2.90 (-1.02%)
GE   81.86 (-1.65%)
DIS   108.49 (-0.96%)
AMC   5.04 (-8.53%)
PFE   43.63 (-0.37%)
PYPL   80.85 (-1.20%)
NFLX   356.71 (-1.13%)
NASDAQ:AGLE

Aeglea BioTherapeutics - AGLE Stock Forecast, Price & News

$0.49
-0.02 (-4.00%)
(As of 01/30/2023 12:41 PM ET)
Add
Compare
Today's Range
$0.48
$0.49
50-Day Range
$0.35
$1.27
52-Week Range
$0.34
$4.54
Volume
20,820 shs
Average Volume
404,185 shs
Market Capitalization
$30.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.88

Aeglea BioTherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
286.6% Upside
$1.88 Price Target
Short Interest
Healthy
0.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.21mentions of Aeglea BioTherapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.01) to ($0.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

159th out of 1,049 stocks

Pharmaceutical Preparations Industry

71st out of 514 stocks


AGLE stock logo

About Aeglea BioTherapeutics (NASDAQ:AGLE) Stock

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Stock News Headlines

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Short Interest Update
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Recap: Aeglea BioTherapeutics Q3 Earnings
Aeglea BioTherapeutics Announces European...
See More Headlines
Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Company Calendar

Last Earnings
11/03/2022
Today
1/30/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGLE
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.88
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+283.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-65,800,000.00
Net Margins
-1,471.82%
Pretax Margin
-1,474.87%

Debt

Sales & Book Value

Annual Sales
$18.74 million
Book Value
$1.70 per share

Miscellaneous

Free Float
57,513,000
Market Cap
$30.12 million
Optionable
Optionable
Beta
1.65

Key Executives

  • Jeffrey M. Goldberg
    President, Chief Executive Officer & Director
  • Jonathan D. AlspaughJonathan D. Alspaugh
    Chief Financial & Accounting Officer
  • Scott W. Rowlinson
    Vice President-Research
  • Linda Neuman
    Chief Medical Officer
  • Mark Bechter
    Vice President-Medical Affairs













AGLE Stock - Frequently Asked Questions

Should I buy or sell Aeglea BioTherapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGLE shares.
View AGLE analyst ratings
or view top-rated stocks.

What is Aeglea BioTherapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued twelve-month target prices for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's share price to reach $1.88 in the next twelve months. This suggests a possible upside of 267.6% from the stock's current price.
View analysts price targets for AGLE
or view top-rated stocks among Wall Street analysts.

How have AGLE shares performed in 2023?

Aeglea BioTherapeutics' stock was trading at $0.4499 at the beginning of the year. Since then, AGLE stock has increased by 13.4% and is now trading at $0.51.
View the best growth stocks for 2023 here
.

Are investors shorting Aeglea BioTherapeutics?

Aeglea BioTherapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 604,200 shares, a decline of 39.6% from the December 31st total of 1,000,000 shares. Based on an average daily trading volume, of 1,950,000 shares, the days-to-cover ratio is currently 0.3 days.
View Aeglea BioTherapeutics' Short Interest
.

When is Aeglea BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our AGLE earnings forecast
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.05. The biotechnology company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.63 million. Aeglea BioTherapeutics had a negative net margin of 1,471.82% and a negative trailing twelve-month return on equity of 114.95%.

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?
When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $0.51.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $31.37 million and generates $18.74 million in revenue each year. The biotechnology company earns $-65,800,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

The company employs 101 workers across the globe.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.

This page (NASDAQ:AGLE) was last updated on 1/30/2023 by MarketBeat.com Staff